# Celadon Pharmaceuticals PLC 140.9% potential upside indicated by Canaccord Genuity

- Link: https://www.directorstalkinterviews.com/celadon-pharmaceuticals-plc-140.9-potential-upside-indicated-by-canaccord-genuity/4121130332
- Published: 2023-10-20T14:06:02+01:00
- Author: Charlotte Edwards

**Celadon Pharmaceuticals PLC** with ticker (LON:CEL) now has a potential upside
of 140.9% according to Canaccord Genuity.
Canaccord Genuity set a target price of
235 GBX for the company, which when compared to the Celadon Pharmaceuticals PLC 
share price of 98 GBX at opening today (20/10/2023) indicates a potential upside
of 140.9%. Trading has ranged between 48 (52 week low) and 189 (52 week high) with
an average of 28,813 shares exchanging hands daily. The market capitalisation at
the time of writing is £64,343,863.Celadon Pharmaceuticals Plc is a United Kingdom-
based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing
and supply of cannabinoid-based medicines. The Company is focused on growing indoor
hydroponic cannabis initially for the chronic pain market. It is also focused on
improving the quality of life for chronic pain sufferers, as well as exploring the
potential of cannabinoid-based medicines for other conditions, such as autism and
multiple sclerosis. The Company’s facility comprises an indoor, closed-loop hydroponic
system to ensure cannabis plants are cultivated under a highly specific climate,
light and with irrigation control. The Company’s subsidiary, LVL Health is a medical
cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory
agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal
products to treat chronic pain in the United Kingdom.

Share on: